Search
Registration & Accommodation
Register Now
Registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities during breaks and welcome reception
Catering during meeting hours incl.
Registration & accommodation
Register here
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Education Committee
Current committee members
Konstanze Döhner, Germany (Chair)
Kirsten Grønbæk, Denmark (Vice-Chair)
Meritxell Alberich Jordà, Czech Republic (Councilor)
Antonio Almeida, Portugal (EHA President)
Nuno Borges, United Kingdom (YoungEHA representative)
Gianluca Gaidano, Italy (Chair Community and Stakeholder Committee)
Jose Tomás Navarro Ferrando, Spain (Chair Curriculum-Exam Committee)
Anna Porwit, Sweden (EHA…
SWG Educational Activities
EventsSWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.
Read moreThe glamorous life of parenthood and medicine
The glamorous life of parenthood and medicine
By Ana Zelić Kerep, MD (YoungEHA Ambassador)
Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…
Current status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- »